A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Connor Clark & Lunn Investment Management Ltd. lowered its position in Novartis AG (NYSE:NVS – Free Report) by 95.6% in the 4th quarter, according to the company in its most recent Form 13F filing ...

Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...